Online Shopping Customer Service 0300 3033380*

Shopping Cart

Health Advice
Main Menu



Exelon patch for Alzheimer's approved by NICE for use on the NHS PDF Print Email

NICE issues new Alzheimer's guidance for Exelon patch treatment.


Novartis Pharmaceuticals UK has welcomed the update to National Institute for Health and Clinical Excellence (NICE) guidance TA1111 and is pleased that the Exelon Patch (rivastigmine transdermal patch) has also been recommended as a cost-effective option for the treatment of mild to moderate Alzheimer's disease. The company states that the Exelon Patch is the first and only transdermal patch licensed for the symptomatic treatment of mild to moderately severe Alzheimer's dementia and is an important treatment option as it reduces the patient pill burden, provides visual reassurance of compliance for the carer and has a preferable side effect profile compared with oral Exelon (rivastigmine) capsules.


The Exelon Patch delivers treatment through the skin into the bloodstream, bypassing the stomach and limiting interactions with any other drugs that the patient may be taking. This means that for most patients it can be a more tolerable treatment option. Professor June Andrews, Director of the Dementia Services Development Centre at the University of Stirling said: "People with dementia and their carers have a lot to contend with, so it's a relief that at last those in the early stages of Alzheimer's disease will have access to medication. Then they can get on with taking the other steps they need to keep well, and enjoy life as much as possible."